DEF: BioAtla, Inc. Announces 2025 Annual Meeting of Stockholders and Proxy Statement

BioAtla, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.

Summary

• BioAtla, Inc. is holding its 2025 Annual Meeting of Stockholders on June 18, 2025, at 8:00 a.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of April 21, 2025, are entitled to vote.
• The meeting will address the election of three Class II directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and a non-binding advisory vote on executive compensation.
• The board of directors recommends voting FOR the election of each director nominee, FOR the ratification of Ernst & Young LLP, and FOR the approval of executive compensation.
• As of the record date, April 21, 2025, there were 58,415,955 shares of common stock outstanding and entitled to vote.
• The board of directors consists of seven directors divided into three classes with staggered three-year terms.
• The company achieved key corporate performance goals in 2024 related to clinical development milestones, research and development goals, and strategic objectives.
• In February 2024, the Compensation Committee increased the base salaries for each of the NEOs.
• In February 2024, the Compensation Committee granted RSUs to each of our NEOs.
• The company has adopted stock ownership guidelines for its executives to better align the executives' interests with those of our stockholders.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and informative tone. The company highlights its achievements and commitment to good governance, contributing to a moderately positive sentiment.

Positives

• The board of directors is committed to good corporate governance practices.
• The company has a compensation recovery policy in place.
• The company prohibits hedging and pledging activities by executive officers, employees, and directors.
• The company achieved key corporate performance goals in 2024 related to clinical development milestones, research and development goals, and strategic objectives.
• The company has adopted stock ownership guidelines for its executives to better align the executives' interests with those of our stockholders.

Risks

• The company operates in a highly competitive and rapidly evolving market.
• The market for skilled personnel in the biotechnology and biopharmaceutical industries is very competitive.

Future Outlook

The company aims to develop and commercialize innovative antibody-based therapeutics for solid tumors, decreasing systemic toxicities and improving efficacy.

Management Comments

• Jay M. Short, Ph.D., Co-founder, Chief Executive Officer and Chairman of the Board of Directors, cordially invited stockholders to attend the 2025 Annual Meeting of Stockholders.
• The board of directors believes that the most effective compensation program is designed to attract and reward talented individuals who possess the skills necessary to support our business objectives and create long-term value for our stockholders, expand our business, and assist in the achievement of our strategic goals.

Industry Context

The document reflects standard corporate governance practices for publicly traded biopharmaceutical companies, including the holding of annual meetings, the election of directors, and the review of executive compensation.

Comparison to Industry Standards

• The compensation peer group consists of 23 US-based, public pre-commercial biopharmaceutical companies.
• The peer group companies are in Phases 1 to 3 of clinical trials, preferably with a focus in oncology.
• The peer group companies have a market capitalization between approximately $100 million and $750 million.
• The peer group companies have a headcount generally under 200 employees.
• The company's compensation practices are aligned with those of its peer group, including the use of base salaries, annual cash incentives, and long-term equity awards.

Related Party Transactions

• BioAtla has a Clinical Trial Services Agreement and a Global Transaction Agreement with Himalaya Therapeutics SEZC, a related party due to Dr. Short's and his spouse's roles within Himalaya.
• For the twelve months ended December 31, 2024, BioAtla recognized $2.2 million in research and development expense related to the transactions with Himalaya.

Stakeholder Impact

• The proposals being voted on will impact shareholders through the election of directors and decisions regarding executive compensation.
• The company's performance and strategic direction will affect employees, customers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting.
• The company will disclose voting results on a Current Report on Form 8-K that we will file with the SEC within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Executive Compensation, Director Election, Ernst & Young, Stockholders, Corporate Governance, BioAtla